The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality!

You missed The inaugural Targeted Radiopharmaceuticals Target Selection & Drug Design Summit, your dedicated forum to advancing novel radiopharmaceutical drug discovery. Attendees had the chance to delve deep into target mining, screening, discovery and selection from ROR1, uPAR, B7-H3, NECTIN-4, CAIX and more. They developed an understanding in radiobiological, radiodecay and radiation absorption mechanisms to inform optimal targeting strategies from small molecule, peptide, nanobodies, antibody fragments as well as linker and chelator technologies for enhanced PK. Bringing it all together, attendees gained a commercial perspective to enhance your strategic decision-making in target selection and novel drug rationale within this highly dynamic field.

The 2025 conference incorporated key insights from radiopharmaceuticals’ leading drug discovery minds from medicinal chemistry, radiobiology, biology, discovery, R&D, pharmacology, computational biology, commercial strategy and many more. This was the only global opportunity to gain practical insights into your approaches, from target selection to drug design.

Uniting the discovery experts pioneering the field, join us next year to understand exactly what targets match the strong therapeutic index of TRPs and uncover optimal targeting strategies for stellar drug discovery!